FAULDING ACQUIRES RIGHTS TO PACLITAXEL IN EUROPE.International pharmaceutical and healthcare company, F H Faulding & Co Limited (Faulding), Adelaide, South Australia South Australia, state (1991 pop. 1,236,623), 380,070 sq mi (984,381 sq km), S central Australia. It is bounded on the S by the Indian Ocean. Kangaroo Island and many smaller islands off the south coast are included in the state. , has announced that Faulding Pharmaceuticals, its global pharmaceuticals division, had entered into a long-term agreement with NaPro Biotherapeutics, Inc (NaPro) relating to the marketing and sale of paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); by Faulding Pharmaceuticals throughout Europe. The agreement adds to existing arrangements between the two companies providing for the sale by Faulding of Anzatax(TM) brand paclitaxel throughout Australia, Asia, South Africa, the Middle East and Latin America. Under the agreement, NaPro will supply paclitaxel raw material exclusively to Faulding to formulate and finish the product at its facility located in Mulgrave, Victoria. The final proprietary paclitaxel formulation will then be marketed and sold by Faulding in Europe. Under the agreement, Faulding will pay an upfront licensing fee to NaPro of US$7.5 million and share equally in the net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight of the product in the new territories. Frank Condella, president & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Faulding Pharmaceuticals, said "The Anzatax(TM) product is a successful and strategically important one for Faulding Pharmaceuticals in Australia, as well as countries in Asia, the Middle East and increasingly in Latin America. Our success with the product to date in this broad and diverse range of countries gives us every confidence that we will obtain good returns from it in Europe. "We are pleased to extend our strong relationship with NaPro to this large market and to continue to build both our core oncology franchise and our branded product portfolio." Paclitaxel is the world's largest selling antineoplastic antineoplastic /an·ti·neo·plas·tic/ (-ne?o-plas´tik) 1. inhibiting or preventing development of neoplasms; checking maturation and proliferation of malignant cells. 2. an agent that so acts. (anti-cancer) drug. Paclitaxel sales in Europe were estimated at US$330 million for the year ended December 2000. Paclitaxel is indicated for the secondary treatment of metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast and ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast , lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. and primary treatment of ovarian cancer. Paclitaxel is currently sold in Europe by the Bristol-Myers Squibb Company under the Taxol(R) brand. Faulding expects to launch paclitaxel in Europe after expiration of data exclusivity protection in 2003. Faulding is a worldwide health and personal care company which is publicly listed on the Australian Stock Exchange Australian Stock Exchange (ASX) Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. . Faulding's principal businesses are oral and injectable generic and branded pharmaceuticals, consumer health products, the provision of distribution and retail management services to pharmacies and logistics management services to hospitals. Faulding markets its products and is represented in more than 70 countries. NaPro Biotherapeutics, Inc., headquartered in Boulder, Colorado, is a biopharmaceutical company focussed on the development, production and licensing of complex natural-product pharmaceuticals as well as the development and licensing of novel genetic technologies for applications in agribiotechnology, pharmacogenomic, and human therapeutic and diagnostic applications. For more information, call +61 8 8205 6500. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion